Dallas, TX -- (SBWIRE) -- 07/08/2015 -- The report "Acinetobacter Infections - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/acinetobacter-infections-pipeline-review-h1-2015-market-report.html

It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. Companies discussed in this Acinetobacter Infections Pipeline Review H1 2015 report include Achaogen Inc., Adenium Biotech ApS, AmpliPhi Biosciences Corporation, Aridis Pharmaceuticals LLC, AstraZeneca PLC, AvidBiotics Corp., ConjuGon, Inc., Emergent BioSolutions Inc., FAB Pharma, LegoChem Biosciences, Inc, Melinta Therapeutics, Inc, Microbiotix, Inc., Northern Antibiotics Oy, Nosopharm SAS, Novan, Inc., Omnia Molecular Ltd., Pfizer Inc., Phylogica Limited, Sarepta Therapeutics, Inc., Sealife PHARMA GMBH, Shionogi & Co., Ltd., Synthetic Biologics, Inc., Techulon, Inc., Trana Discovery, Inc., Vaxdyn, S.L.

Drug Profilesdiscussed in this report includes A-3APO, AA-139, ACHN-975 Prodrug, Antibiotics to Inhibit tRNA For Hospital-Acquired Gram-Negative Bacterial Infections, Antisense Oligonucleotide for Acinetobacter baumannii Infections, Antisense Oligonucleotide for Acinetobacter Baumannii Infections, AR-401, Biologics for Acinetobacter Baumanii, BXN-112, Cephalosporin + Beta-Lactamase Inhibitor, EV-035, Fab-001, GN-4474, LCB-100200, MBX-1162, MDN-0057, MDN-0058, MDN-0059, MDN-0060, Monoclonal Antibodies for Gram-Negative Bacterial Infections, NAB-7061, NAB-739, NAB-741, NOSO-95300, NVN-1000, NVN-4428, Recombinant Proteins to Disrupt Bacterial Cell Membrane for Bacterial Infections, RX-05, RXP-873, S-649266, Second Generation Apidaecin Analogs for Gram-Negative Bacterial Infections, SLP-0905, Small Molecule for Acinetobacter baumannii Infections, Small Molecule for Gram-Negative Nosocomial Infections, Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections, Small Molecules for Gram-Negative Bacterial Infections, SYN-001, VXD-001, VXD-003.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=394569 . (This is a premium report priced at US$2000 for a single user License.)

Table of Contents

List of Tables
Number of Products under Development for Acinetobacter Infections, H1 2015 12
Number of Products under Development for Acinetobacter Infections - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Development by Companies, H1 2015 (Contd..2) 21
Products under Investigation by Universities/Institutes, H1 2015 22
Acinetobacter Infections - Pipeline by Achaogen Inc., H1 2015 23
Acinetobacter Infections - Pipeline by Adenium Biotech ApS, H1 2015 24
Acinetobacter Infections - Pipeline by AmpliPhi Biosciences Corporation, H1 2015 25
Acinetobacter Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2015 26
Acinetobacter Infections - Pipeline by AstraZeneca PLC, H1 2015 27
Acinetobacter Infections - Pipeline by AvidBiotics Corp., H1 2015 28
Acinetobacter Infections - Pipeline by ConjuGon, Inc., H1 2015 29
Acinetobacter Infections - Pipeline by Emergent BioSolutions Inc., H1 2015 30
Acinetobacter Infections - Pipeline by FAB Pharma, H1 2015 31
Acinetobacter Infections - Pipeline by LegoChem Biosciences, Inc, H1 2015 32
Acinetobacter Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015 33
Acinetobacter Infections - Pipeline by Microbiotix, Inc., H1 2015 34
Acinetobacter Infections - Pipeline by Northern Antibiotics Oy, H1 2015 35
Acinetobacter Infections - Pipeline by Nosopharm SAS, H1 2015 36
Acinetobacter Infections - Pipeline by Novan, Inc., H1 2015 37
Acinetobacter Infections - Pipeline by Omnia Molecular Ltd., H1 2015 38
Acinetobacter Infections - Pipeline by Pfizer Inc., H1 2015 39
Acinetobacter Infections - Pipeline by Phylogica Limited, H1 2015 40
Acinetobacter Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2015 41
Acinetobacter Infections - Pipeline by Sealife PHARMA GMBH, H1 2015 42
Acinetobacter Infections - Pipeline by Shionogi & Co., Ltd., H1 2015 43
Acinetobacter Infections - Pipeline by Synthetic Biologics, Inc., H1 2015 44
Acinetobacter Infections - Pipeline by Techulon, Inc., H1 2015 45
Acinetobacter Infections - Pipeline by Trana Discovery, Inc., H1 2015 46
Acinetobacter Infections - Pipeline by Vaxdyn, S.L., H1 2015 47
Assessment by Monotherapy Products, H1 2015 48
Assessment by Combination Products, H1 2015 49
Number of Products by Stage and Target, H1 2015 51
Number of Products by Stage and Mechanism of Action, H1 2015 53
Number of Products by Stage and Route of Administration, H1 2015 55
Number of Products by Stage and Molecule Type, H1 2015 57
Acinetobacter Infections Therapeutics - Recent Pipeline Updates, H1 2015 108
Acinetobacter Infections - Dormant Projects, H1 2015 112

Explore more reports on Infectious Diseases Therapeutics industry at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.